Navigation Links
Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
Date:6/11/2008

GOTHENBURG, Sweden, June 11 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced a new collaborative agreement with AstraZeneca. Under the agreement Cellectricon will provide AstraZeneca with two of its new groundbreaking high throughput platform, Dynaflow(R)HT, for ion channel screening.

Cellectricon and AstraZeneca formed and announced a collaboration in May 2006 aiming to find a solution to major bottlenecks in ligand gated ion channel screening. The results from this collaboration have successfully demonstrated the unique performance of Cellectricon's cell-based microfluidic screening platform. It has clearly demonstrated the opportunity to introduce the fully automated Dynaflow(R)HT System with unmatched level of stability and throughput while still delivering unique measurement data quality. The Dynaflow(R)HT System will be launched and commercially available in 2009.

"Collaborating with AstraZeneca has been most rewarding," says Jonas Ohlsson, CEO at Cellectricon. "Driven by solving bottlenecks in drug discovery, Cellectricon's strategy is to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations."

"This collaboration aims to accelerate our efforts in ion channel drug discovery and has been very fruitful to date. We look forward to working with the Dynaflow@HT Systems and see the impact of their throughput and cost effectiveness," says Dr. Jan-Erik Nystrom, VP Local Discovery Research Area CNS & Pain Control, Sodertalje, Sweden.

"The strength of this platform is that it is based on many years of cutting-edge academic and industrial research in ion channel drug discovery. I am happy to see us taking a new step together with a leading partner in advancing it further," says Dr. Jon Sinclair, VP Research & Development at Cellectricon.

About Cellectricon

Cellectricon AB (http://www.cellectricon.com), a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007 the company increased its annual revenue by almost 50%. In 2008-2009 the company will launch two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.


'/>"/>
SOURCE Cellectricon AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
2. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
5. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
6. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
7. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
8. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
9. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
10. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
11. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/10/2017)... ... 10, 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, ... The bold new look is part of a transformation to increase awareness, appeal ... growth period. , It will also expand its service offering from its signature gourmet ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced the ... NIH to develop RealSeq®-SC (Single Cell), expected to be ... small RNAs (including microRNAs) from single cells using NGS ... the need to accelerate development of approaches to analyze ... "New techniques for measuring levels of mRNAs ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in ... professor in Harvard University’s Departments of Physics and Astronomy, has been selected for membership ... the winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):